By Colin Kellaher


AbbVie said Wednesday that a Phase 2 study of its experimental drug telisotuzumab-vedotin, or teliso-V, showed a reduction in disease in patients with a type of non-small cell lung cancer.

AbbVie said the study evaluating teliso-V in patients with c-Met protein overexpression, epidermal growth factor receptor wild type, advanced/metastatic nonsquamous non-small cell lung cancer showed a reduction in the disease in 35% and 23% of c-Met High and c-Met Intermediate patients, respectively.

In addition, the company said the study results showed that patients' tumors continued to respond to treatment for a median duration of nine months and 7.2 months across c-Met High and c-Met Intermediate patients, respectively, with the patients surviving for a median of 14.6 months and 14.2 months, respectively.

Lung cancer is the leading cause of cancer death around the world, with non-small cell lung cancer accounting for about 85% of all cases.

AbbVie said C-Met protein overexpression is found in about 25% of advanced epidermal growth factor receptor wild type non-small cell lung cancer patients and is associated with a poor prognosis.

The North Chicago, Ill.-based biopharmaceutical company said it plans to hold talks with global health authorities on the potential to support an accelerated approval of teliso-V.


Write to Colin Kellaher at colin.kellaher@wsj.com


(END) Dow Jones Newswires

11-29-23 0957ET